Carlyle Group (NYSE:CG) is reportedly in exclusive talks to acquire Baxter International Inc.’s (NYSE:BAX) kidney-care spinoff, Vantive, in a deal valued at over $4 billion, including debt. The companies began exclusive negotiations in late June, the Wall Street Journal reported, citing sources familiar with the matter. An agreement could be announced in the coming weeks, though there’s a possibility that the discussions might fall through or another bidder could emerge. Baxter had announced plans to spin off Vantive in the second half of this year, intending ...